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1  
 Abstract  1 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a 2 
considerable impact on patients’ quality of life. Despite the plethora of clinical trials 3 
for SLE since the turn of the millennium, only one new treatment has been approved 4 
for the condition and the overall pace of successful drug development remains slow. 5 
Nevertheless, the myriad of clinical studies has yielded insights that have informed 6 
and refined our understanding of eligibility criteria, outcome measures and trial 7 
design in SLE. In this review, we highlight the achievements of clinical trials as well 8 
as the major pitfalls that have been identified in drug development for SLE and, in 9 
doing so, identify areas where collaboration and consensus will be important to 10 
facilitate progress. 11 
 12 
   13 
2  
 INTRODUCTION 1 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that follows a 2 
relapsing-remitting course. It is characterized by the production of autoantibodies 3 
against a range of autoantigens including nuclear components, immune-mediated 4 
inflammation in a variety of organs, and the accrual of organ damage over time.[1] 5 
Despite its prevalence (approximately 70 cases per 100,000 people)[2-6] and 6 
considerable impact on quality of life,[7, 8] treatment options remain inadequate and 7 
the development of novel therapies has been slow. 8 
Only one new drug, belimumab, has been approved for the treatment of SLE in more 9 
than 60 years.[9-11] While numerous other drugs and biologics have entered clinical 10 
trials for SLE since the turn of the millennium, development of most has been halted 11 
at various stages.[12-14] Although some of these failures may be related to 12 
inefficacy of the investigational product or adverse events, there is general 13 
consensus in the community that problems with trial design and operation may have 14 
contributed to the unsuccessful outcomes. Notably, however, a number of recent 15 
phase IIb trials (each investigating agents with different modes of action) have 16 
reported positive outcomes,[15, 16] suggesting that new treatment options may be 17 
on the horizon, though the recent failure of a phase III anifrolumab trial to meet its 18 
primary endpoints, reported in the lay press, suggests that there is more to learn. 19 
Although the majority of trials in SLE have failed to meet their primary endpoints, 20 
many of these studies have offered valuable insights that have advanced the field 21 
considerably, including the evolution of thinking about eligibility criteria and outcome 22 
measures. Nevertheless, several important issues remain unresolved, and progress in 23 
these areas will require consensus among the relevant stakeholders. The aim of this 24 
review is to highlight pitfalls in drug development for SLE and identify areas where 25 
collaboration and consensus will be important to facilitate progress. 26 
LESSONS LEARNED FROM PREVIOUS CLINICAL TRIALS IN SLE 27 
Formal clinical trials in SLE have been carried out for nearly two decades, although 28 
many failed to meet their primary endpoints.[12] Post-hoc analyses of these studies 29 
have identified numerous issues related to trial design,[12, 17] prompting 30 
investigators, pharmaceutical companies and regulatory agencies to standardize 31 
aspects, such as entry criteria (by defining thresholds for disease activity and 32 
3  
 autoantibody positivity), outcome measures, preferences for trial duration, and the 1 
choice of background therapy (including regimens for steroid use and tapering).  2 
Many of these issues have been decided pragmatically, often in discussions between 3 
pharmaceutical/biotech companies and regulatory agencies.[12] Whether the final 4 
negotiated approach is the most scientifically valid has often not been determined, 5 
but operationally a “standard” SLE therapeutic trial design has emerged.[9, 10] 6 
Despite previous trial failures, many companies continue to have a strong 7 
commitment towards developing new drugs for SLE. In some cases, this may relate 8 
to promising trends in the trial data that differentiate potential responders from 9 
nonresponders.[18] Other times, it is learning from another company’s successes 10 
and failures.[14] Regardless, the pace of clinical trials in SLE remains brisk.  11 
Some of the failed trials in SLE might have tested agents that were truly ineffective. 12 
However, in other cases it was reasonable to expect success, such as when testing 13 
agents related to compounds that had previously been successful (belimumab versus 14 
tabalumab), agents with strong evidence of efficacy from clinical experience 15 
(rituximab), or agents with extensive pre-clinical experience (abatacept plus 16 
cyclophosphamide). These experiences suggest that the current trial paradigm for 17 
SLE may not be capable of convincingly testing the efficacy of a compound, or 18 
definitively deciding whether or not to advance a compound into phase III. 19 
Disease activity as an entry criterion 20 
One of the earliest trials in SLE examined the efficacy of dehydroepiandrosterone 21 
(DHEA) in 381 patients.[19] Although this study did not meet its primary endpoint, 22 
valuable insights were obtained into the design of clinical trials in SLE. Specifically, a 23 
post-hoc analysis indicated that the primary endpoint was only met in patients with a 24 
baseline SLE Disease Activity Index (SLEDAI) score >2. As such, this was the first 25 
trial demonstrating the potential utility of disease activity as an entry criterion.  26 
Subsequent trials have confirmed the importance of recruiting patients with 27 
moderate-to-high disease activity in order to discern a treatment effect. This has 28 
generally been achieved by specifying disease activity beyond a certain threshold for 29 
inclusion (e.g. SLEDAI ≥6, or a British Isles Lupus Assessment Group (BILAG) score 30 
of B or A, indicating active organ involvement).[14] Post-hoc analysis of the BLISS 31 
trials revealed additional benefits of belimumab treatment in patients with higher 32 
4  
 disease activity (SLEDAI ≥10) at baseline.[20] Notably, this increased benefit 1 
seemed to rely on decreased responsiveness in patients receiving standard of care 2 
only. Thus, the absolute difference in response between the group receiving 3 
standard of care plus belimumab, and the group receiving standard of care alone, 4 
was increased. This observation suggests that standard of care therapy can be 5 
effective in the setting of a clinical trial, and could be especially effective in patients 6 
with mild disease upon entry (despite having apparently failed standard of care 7 
before enrollment). Discerning a response to an experimental agent appears to be 8 
more likely in patients with more active disease, in whom the response to 9 
background therapy is diminished. 10 
Geographic location 11 
International SLE trials have demonstrated major differences in treatment response 12 
according to geographical region. Specifically, sites in developing countries generate 13 
data that indicate a better response to placebo (plus standard of care) compared to 14 
results obtained in the United States or western Europe.[21] The reason for this 15 
discrepancy is uncertain, but might relate to patients’ access (or lack thereof) to 16 
standard of care therapies before entering the trial, and the requirement to 17 
consistently take these medications in the trial setting. A second concern is the 18 
increased frequency of infection[22] as well as trial-related deaths[23, 24] in studies 19 
conducted in developing countries. Part of this may relate to higher rates of certain 20 
infections in these countries, coupled with the lack of access to standard and 21 
emergency medical care. Thus, whilst there are major attractions to recruiting 22 
patients from developing countries (including low expense, rapid enrolment and the 23 
prevalence of active disease), there is a clear need to guard against a greater 24 
placebo response, and to mitigate the intrinsic risk of serious adverse events, in 25 
these regions. 26 
Ancestry/ethnicity 27 
A number of SLE trials have suggested preferential response to treatment in certain 28 
ancestral subsets. The comparative trial of mycophenolate mofetil (MMF) versus 29 
cyclophosphamide (CYC) in lupus nephritis suggested that MMF might be more 30 
efficacious in a primarily African-Ancestry (AA)/Hispanic trial population.[25] In 31 
contrast, the induction phase of the Aspreva Lupus Management Study (ALMS) trial, 32 
with patients of predominantly European Ancestry (EA) did not show any significant 33 
5  
 difference between the two drugs.[26] However, post-hoc analysis suggested an 1 
improved response to MMF in the AA/Hispanic group.[27] These findings were 2 
sufficiently convincing that the 2012 ACR Lupus Nephritis Treatment Guidelines 3 
recommend MMF over CYC as first-line treatment for AA and Hispanic 4 
populations.[28]  Results from the pivotal trials of belimumab suggested that this 5 
agent was not effective in AA patients,[9, 10] although the numbers of AA patients in 6 
these trials were small. In contrast, the results of a pre-specified subgroup analysis 7 
suggested that rituximab might be more efficacious in AA/Hispanic lupus nephritis 8 
patients.[29] However, given the poor recruitment of AA patients into SLE trials, 9 
these findings are at best speculative. Recent systematic reviews of potential 10 
predictors of response to MMF and rituximab have concluded that the overall quality 11 
of evidence supporting differential effects related to ancestry and ethnicity are low, 12 
and further confirmatory studies are needed to discern whether such a difference 13 
exists.[30, 31] Other factors, including the small size of the trials and socioeconomic 14 
status, may have contributed to the result. 15 
Heterogeneity of clinical manifestations 16 
SLE is a heterogeneous disease, involving numerous organ systems. In general, trials 17 
have focused either on generalized SLE or lupus nephritis. In trials of generalized 18 
SLE, it is common to exclude patients with rapidly progressive kidney or CNS 19 
disease.[9, 10] As a result, studies have largely enrolled patients with 20 
mucocutaneous and musculoskeletal involvement. This not only limits the 21 
heterogeneity of the enrolled population, but excludes patients with less common 22 
and more severe disease manifestations. As a result, little information has emerged 23 
on the efficacy of agents in these patients.  24 
Lupus nephritis trials have typically enrolled patients with biopsy-proven nephritis, 25 
although there is considerable variation in the timing of the biopsy relative to trial 26 
entry.[32] As a result, the exact nature of kidney involvement at the time of trial 27 
enrollment may not be certain, owing to the possible role of hypertensive kidney 28 
disease and progressive kidney fibrosis. Moreover, entry has usually been based on 29 
glomerular involvement, despite evidence that interstitial inflammation may play a 30 
more important role in progression to kidney failure.[33] In addition, the level of 31 
proteinuria at baseline might be an important predictor of renal response. For 32 
example, in a trial comparing the addition of abatacept or placebo to background 33 
6  
 MMF in patients with lupus nephritis, those with baseline nephrotic syndrome had a 1 
greater response to abatacept as measured by reduction in proteinuria.[34]  2 
Outcome measures  3 
Although numerous outcome measures were used in early SLE trials, the FDA 4 
released draft guidelines in 2005 to facilitate their standardization.[35] This included 5 
the recommendation of a composite endpoint that could measure clinically 6 
meaningful improvements in active organ systems without worsening in others, and 7 
detect both early and overall changes in disease activity. The FDA seemed to favour 8 
the BILAG;[36] however, the success of the belimumab BLISS trials resulted in 9 
widespread adoption of the SLE Responder Index (SRI)-4 as the primary outcome 10 
measure. The BILAG-Based Composite Lupus Assessment (BICLA) and the SRI-5 11 
were used in unsuccessful phase III trials of epratuzumab and tabalumab, 12 
respectively.[37-39] However, the BICLA was employed as an outcome in successful 13 
phase II trials of anifrolumab[15] and epratuzumab,[40] and in a post-hoc analysis 14 
of an IL-6 receptor antibody,[24] both in generalized SLE.  15 
The decision to adopt the SRI-4 was driven from a retrospective analysis of the 16 
phase II belimumab data, which found that this instrument distinguished active drug 17 
from placebo. This hypothesis was borne out in subsequent trials with both 18 
intravenous and subcutaneous belimumab.[41, 42] In addition, the FDA believed it 19 
was important to determine whether an agent might be effective in some domains, 20 
while at the same time measuring whether deterioration occurs in others. However, 21 
subsequent analyses have shown that the overwhelming contributor to the SRI-4 is 22 
improvement in SLEDAI alone, with very few patients manifesting improvement in 23 
SLEDAI but deterioration in BILAG or Physician’s Global Assessment (PGA).[9, 10] 24 
Since the majority of patients in the belimumab trials had skin and joint involvement, 25 
SLEDAI was sufficient to capture improvement in this case. However, SLEDAI cannot 26 
capture some types of organ involvement, and therefore may not be sufficient for 27 
assessing the outcomes of less common disease manifestations. In addition, higher 28 
baseline SLEDAI scores may improve the ability to detect an SRI-4 response. 29 
It is also important to note that while the SRI-4 continues to be used as the 30 
preferred primary outcome measure in major SLE clinical trials, it is not used as an 31 
assessment in routine clinical practice. This creates a disconnect between clinical trial 32 
7  
 data and information that is meaningful to a practitioner or patient, and might delay 1 
the uptake of newly approved therapies into practice, since physicians are unclear 2 
about the expected clinical response and are often inexperienced at using the 3 
component instruments (SLEDAI, BILAG and PGA). Nevertheless, there is now a 4 
requirement to use BILAG and SLEDAI when assessing patients for treatment with 5 
rituximab or belimumab in the NHS in England.[43-45] However, both of these 6 
instruments have significant limitations, including low inter-observer correlation and 7 
high complexity in the case of the BILAG. Lastly, careful consideration should be 8 
given to the use of flare rather than response as an endpoint.[46] 9 
Collectively, these considerations suggest that a re-evaluation of outcome measures 10 
in clinical trials based on available data might be necessary to develop more clinically 11 
meaningful ways to assess the impact of new therapies. Unfortunately, an initial 12 
attempt to create a novel SLE response index from the belimumab trial data was not 13 
successful.[47] However, a more recent effort based on the BLISS-76 data yielded 14 
the Lupus Multivariable Lupus Outcome Score (LuMOS), a robust outcome measure 15 
that outperformed the SRI-4 and was validated in the BLISS-52 database.[48] If 16 
recapitulated in trials for agents with other mechanisms of actions, LuMOS will be 17 
the first evidence-based SLE outcome measure, and may provide a better means to 18 
assess treatment response in clinical trials.[48] As new outcome measures are 19 
developed, it will be important to perform validation studies examining their 20 
association with longer-term outcomes, quality of life, and cost effectiveness. 21 
The aforementioned FDA guidelines have since been replaced by a finalized 22 
document, which was issued in 2010 and is still operational.[49] This includes 23 
guidance for a range of trial design issues, including statistical considerations. At the 24 
time of release, the FDA issued separate documents for SLE and lupus nephritis, 25 
although the latter was eventually withdrawn and has not yet been replaced. In the 26 
absence of specific guidelines for lupus nephritis, the most effective short-term renal 27 
response measures remain elusive, with different instruments generating significant 28 
variability in the data obtained and the conclusions drawn.[50]  29 
Importantly, the process by which new outcome measures might be incorporated 30 
into SLE clinical trials has not been clearly articulated by the regulatory agencies. 31 
Some outcome measures, such as the Cutaneous Lupus Area and Severity Index 32 
(CLASI) to evaluate skin involvement have been developed by the academic 33 
8  
 community, but not accepted by regulatory authorities as a validated outcome 1 
measure in clinical trials. As a result, nearly all SLE trials rely on evidence derived 2 
from the standard composite outcome measures described in the 2010 FDA guidance 3 
document. Given the recent developments and lessons learned from SLE trials (both 4 
successful and unsuccessful), we firmly believe that it is time for the regulatory 5 
guidance to be revised through collaboration between a range of stakeholders, 6 
including physicians, patients, members of industry, and regulatory agencies who 7 
have expertise in this area. In addition, evidence-based guidance for outcomes in 8 
lupus nephritis are sorely needed. An even better option would be to propose and 9 
adopt new trial designs and outcome measures through an accelerated process that 10 
could bypass a traditional guidance document. 11 
The role of serological assessments in entry criteria 12 
The use of serological biomarkers for enrollment in SLE trials is a relatively recent 13 
development, having become standard practice within the past decade. This 14 
approach was based largely on a post-hoc analysis of phase II belimumab data,[51] 15 
which revealed a subset of autoantibody positive patients who responded to  16 
belimumab better than their seronegative counterparts. Before this, eligibility was 17 
based primarily on the ACR Classification Criteria for SLE (which do not require a 18 
serological criterion) and established indices of disease activity, with no stand-alone 19 
serological component.[19, 52] While SLEDAI includes measures of anti-DNA and 20 
complement levels, antinuclear antibody [ANA] positivity was not always required for 21 
trial entry. 22 
Although ANA, anti-DNA, low complement C3 and C4, and/or anti-Smith 23 
autoantibodies are now commonly used as entry criteria, there is no consensus on 24 
the specific autoantibody or serological marker required, nor the method used to 25 
measure it. As previously noted, the use of autoantibody positivity to classify patients 26 
was based on phase II data from a B-cell directed therapy, providing some rationale 27 
for its use in that context.[51] However, the use of serological positivity to subset 28 
patients in trials of agents not directed toward B cell function may not be appropriate.  29 
In reality, this approach has been embraced in an attempt to confirm that patients 30 
enrolled in trials actually have SLE. It is thought that a positive ANA test increases 31 
that likelihood, and therefore the test has been widely employed as an entry criterion. 32 
9  
 Of note, the recent SLE classification criteria developed by the American College of 1 
Rheumatology and the European League Against Rheumatism require a positive ANA 2 
at 1:80 titer.[53] However, given its poor specificity, variability between assays, and 3 
the observation that patients with SLE may convert to a negative ANA over time and 4 
with immunosuppressive therapy,[54] the use of a positive ANA to classify patients 5 
and assess eligibility in clinical trials is problematic. Using more specific tests, such as 6 
a positive anti-DNA, imposes additional problems.[55] Restricting trials to anti-DNA 7 
positive patients would exclude approximately 40% of SLE patients because of the 8 
lesser sensitivity of these assays. Similarly, a requirement for low complement levels 9 
would exclude many patients, particularly those in non-renal lupus trials. In short, 10 
the utility of specific serologic testing for assessing eligibility in SLE trials has not 11 
been carefully examined, and will require thoughtful consideration in the future. 12 
Biomarkers  13 
Apart from the use of autoantibodies, and possibly complement levels, no biomarkers 14 
are currently accepted as informative in SLE clinical trials. Recent data have indicated 15 
that anifrolumab, a monoclonal antibody to the type 1 interferon receptor, might be 16 
effective in generalized SLE based on phase II data.[15] These results also 17 
suggested that the treatment was only effective in individuals who had increased 18 
expression of certain interferon-responsive gene products. There are phase III trials 19 
currently underway with secondary endpoints to assess whether this “interferon 20 
signature” might facilitate stratification, and thus serve as a companion diagnostic to 21 
identify patients with a greater likelihood of responding to treatment.[56] If 22 
successful, this would represent the first biomarker for selecting and monitoring the 23 
treatment of patients with SLE. 24 
Background therapy 25 
Most trials in SLE test new agents on the background of standard of care therapy. 26 
This stems largely from investigators’ concerns about the development of irreversible 27 
organ damage in the placebo group if adequate background medication were not 28 
continued. However, there are a number of problems with this approach.  29 
First, standard of care can be quite effective in many patients, leaving a narrow 30 
window for improvement with the experimental agent, particularly if patients take 31 
their medications more reliably in the trial setting.[57] Secondly, there is no 32 
10  
 consensus on what constitutes ‘standard of care’, meaning that participants within 1 
the same trial may be treated with different background medications. Thirdly, many 2 
trials permit variation in the dosing of background medication for a period of time 3 
before or during the study, making it even more difficult to discern benefit from the 4 
experimental agent. Finally, recent work from the Systemic Lupus International 5 
Collaborating Clinics (SLICC) cohort has revealed substantial variation in the dose of 6 
steroids used across centers. While patient and disease factors contribute to this 7 
variation, differences between centers suggest that physician-related factors also 8 
contribute. Such patient-independent heterogeneity in steroid use will contribute to 9 
‘noise’ in multicenter trials and increase the likelihood of type two errors. A period of 10 
standardization in steroid use prior to randomization may be necessary to address 11 
such variation as was done in the April-SLE atacicept trial.[23, 58]  12 
Two recent studies that support the possibility of minimizing background therapy 13 
through steroid tapering are the phase II anifrolumab and voclosporin trials,[15, 59] 14 
both of which reported low placebo responses. These studies suggest, though do not 15 
prove, that lowering standard of care therapy in a safe manner might permit better 16 
discernment of the benefit of the experimental agent. This would also be beneficial 17 
for the safety of trial participants, by providing clearer criteria for rescue therapy or 18 
study withdrawal. 19 
Time and expense  20 
Clinical drug development is very costly and time-consuming. This has frequently 21 
prompted pharmaceutical companies to design clinical development programs that 22 
save time and utilize the fewest number of patients. Since drug approval requires 23 
data in two well-designed clinical trials,[60] the standard phase I through III 24 
programs have often been truncated, typically by short-circuiting phase II trials or 25 
even treating them as pivotal in order to save time and resources. As a result, phase 26 
III trials are often initiated without proper dose-ranging or robust power calculations, 27 
and with little information on the optimal regimen and outcome measures. In 28 
addition, the potential contribution of ancestry to trial outcomes is frequently 29 
neglected (the FDA has requested additional trials of belimumab in patients of 30 
African descent). The impact of body composition may also be underestimated. Most 31 
trials use fixed-dose drug regimens regardless of body mass index, which does not 32 
account for the potential pharmacokinetic variation between patients. 33 
11  
 While understandable in terms of cost and efficiency, agents such as tabalumab and 1 
epratuzumab[61] may ultimately have failed because of these drawbacks. Thus, the 2 
effectiveness of phase III trials hinges critically on the data obtained in phase II, 3 
highlighting the need to conduct more extensive studies at this stage.  4 
AREAS IN NEED OF COLLABORATION AND CONSENSUS  5 
The authors believe that there are two major areas in which collaboration and 6 
consensus would be useful. The first relates to data that are already available from 7 
clinical trials in SLE. Over 5,000 patients have participated in these studies, providing 8 
a wealth of data that may help us to answer important questions about trial design 9 
and conduct. The second area relates to issues that cannot be addressed using the 10 
existing trial data alone. Questions falling within each of these areas are listed in 11 
Table 1.  12 
Table 1. Aspects of SLE drug development that are in need of collaboration and 13 
consensus 14 
Questions that can be addressed using existing clinical trial data 
• Adverse events 
o What factors influence adverse events in SLE trials?  
o When do adverse events occur?  
o Are adverse events more likely during the first few weeks of the trial when 
steroid doses tend to be higher?  
o What is the evidence that adverse events are influenced by steroid dose 
and/or background immunosuppressants?  
o Are adverse events more common in particular geographic regions or 
certain types of research institution than others? 
• Outcome measures 
o Is the SRI the most appropriate outcome measure?  
o Does it matter which version of the SRI is used?  
o Can we simplify this by focusing only on improvement in disease activity, 
or change in disease activity using a single instrument? 
o Which outcome measures should be used in generalized SLE trials, and 
which in lupus nephritis trials? 
o Should we consider flare prevention as a primary outcome measure? 
o Which outcome measures have performed best in lupus nephritis trials? 
12  
 Are these endpoints influenced by the duration of renal involvement, time 
since renal biopsy, the result of renal biopsy and/or a patient’s treatment 
history? 
• Background therapy 
o Do trial outcomes differ with different background regimens? 
o What is the role of background steroids?  
o Should the target steroid dose depend on the patient’s baseline dose or 
body weight?  
o Should there be a ‘run-in’ period to standardize steroid use prior to 
randomization? 
• Regional differences 
o Are there consistent regional differences in the use of background 
medications, or the development of adverse events? 
o Should trials require a mandatory number of subjects of different 
ancestries? How should ancestry be determined? How should mixed 
ethnicity be dealt with? 
• Others 
o What are the best biomarkers to judge efficacy? Are they specific to the 
agent’s mechanism of action, or related to disease manifestations? 
o Is autoantibody stratification useful and/or necessary? 
o Will an AUC approach be better than a landmark analysis? 
Questions that require expertise and consensus beyond what is available from 
clinical trial data 
• Trial design 
o What is the most appropriate length of a trial? Should there be “induction” 
and “maintenance” trials? 
o What is the most appropriate design of a non-renal SLE trial? Should we 
enroll active patients and measure improvement in disease activity, or 
should we be measuring “time to flare” instead after initial treatment of 
flare?   
• Patient-reported outcomes 
o What is the role of PROs, and which is the most appropriate to use? 
o What is the role of PROs in clinical trial design and drug approval? Should 
drugs be approved based on improvement in PROs? What is the 
contribution of comorbidities to PROs? 
• Background therapy 
o What is “standard of care”? Are standard of care regimens used for clinical 
13  
 or ethical reasons? 
o Should there be a mandatory steroid taper versus the commonly used 
“suggested” steroid taper? Should steroid taper to a certain dose be part 
of the primary endpoint? 
• Other 
o What does “treat to target” really mean in lupus? 
 
AUC: area under curve; PRO: patient-reported outcome; SLE: systemic lupus erythematosus; SRI: SLE 1 
responder index. 2 
The current landscape 3 
Various initiatives are already taking shape to address the outstanding issues in SLE 4 
clinical trials. Among these is the Definitions of Remission In SLE (DORIS) taskforce, 5 
an international collaboration between 60 specialists and patient representatives to 6 
formulate a universal definition of ‘remission’ in SLE, in line with treat-to-target 7 
recommendations.[62] The taskforce recently published a framework for this 8 
purpose comprising eight key statements, as well as three principles to guide the 9 
refinement of this definition in future.[62] Since remission is rarely a goal in SLE 10 
trials, because it is too stringent and hard to achieve,[63] optimal trial design will 11 
require the development of alternative endpoints. To this end, one group of 12 
investigators is developing the Lupus Low Disease Activity State (LLDAS) for 13 
generalized SLE,[64] and another group has developed a low disease activity (LDA) 14 
outcome.[65] These new endpoints could initially be incorporated in SLE trials as a 15 
secondary endpoint for comparison with existing instruments, and might eventually 16 
replace SRI or SLEDAI as the primary outcome measure. For example, LLDAS has 17 
been incorporated as a secondary endpoint in the currently enrolling BLISS-BELIEVE 18 
trial sponsored by GlaxoSmithKline.[66] 19 
Further to these efforts, the Lupus Industry Counsel is working with Outcome 20 
Measures in Rheumatology (OMERACT) to develop new instruments by reanalyzing 21 
existing trial data,[67] and the Lupus Foundation of America (LFA) is developing a 22 
system of tools (dubbed LFA-REAL) for the measurement of both systemic and 23 
organ-specific disease activity.[68]  24 
Another recent focus of collaboration in SLE is the identification of genetic and/or 25 
phenotypic markers for patient stratification. The Innovative Medicines Initiative 26 
14  
 (IMI) is an EU-based, public-private initiative to improve the drug development 1 
process in Europe. Among the projects currently being conducted under this initiative 2 
is PRECISESADS, which is bringing together academic, clinical and industry partners 3 
to identify biomarkers that will assist with developing a new taxonomy for systemic 4 
autoimmune diseases, including SLE.[69] PRECISESADS therefore aims to group 5 
patients with a shared pathogenesis, rather than using standard diagnostic and 6 
clinical classification criteria.[70]  7 
In the UK, the Medical Research Council (MRC) is funding MASTERPLANS 8 
(MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified 9 
approaches).[71] MASTERPLANS seeks to identify patient-level variables, including 10 
genetic and other biomarkers, that define an endotype of response in SLE patients, 11 
with an initial focus on mycophenolate and rituximab. The contribution of industry 12 
partners to these initiatives is particularly valuable, given their large datasets and 13 
extensive libraries of patient samples. Moreover, once new biomarkers are identified, 14 
their uptake and use in clinical trials by industry partners will be crucial for their 15 
validation.  16 
CONCLUSION 17 
While most recent trials in SLE have failed to meet their primary endpoints, many 18 
have offered valuable insights that have shaped the field as we know it today. 19 
Nevertheless, meaningful change from this point forward will require community-20 
wide consensus, including academia, industry and patient organizations, in dialogue 21 
and partnership with regulators and payers. In short, it is imperative that common 22 
goals are identified and that the community speaks with one voice. 23 
By forging new collaborations, re-analyzing existing datasets, and pooling data from 24 
multiple sources in a ‘pre-competitive’ way, we will gain new insights to help improve 25 
trial design using evidence-based and data-driven approaches. The ability to identify 26 
subsets of disease with a common pathogenic mechanism, or patient endotypes 27 
more likely to respond to a particular therapeutic agent, will also allow us to offer 28 
patients the right drug for their condition in a timely manner, and shorten the time 29 
from diagnosis to disease control. Keeping the patient at the forefront of our efforts 30 
should spur us to achieve consensus on the way forward, and steer efforts to refine 31 
the guidance for trial design and conduct. 32 
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